According to a multi-center clinical trial led by researchers at the Stanford University School of Medicine, a new type of immunotherapy seems to be safe for patients with blood cancer called non-Hodgkin’s lymphoma.
The therapy combines experimental antibodies developed by researchers at Stanford University and commercially available anti-cancer antibodies to rituximab. It referred Hu5F9-G4 experimental protein antibody blockade of CD47 , of CD47 suppressed immune attack against cancer cells. The combination of two antibodies is used to treat people with two types of non-Hodgkinov lymfóm: diffuse large B- cell lymphoma and follicular lymphoma.
V roku 2010 výskumníci pod vedením MD Irvinga Weissmana, riaditeľa Stanfordského ústavu pre kmeňové bunky a regeneračnú medicínu, preukázali, že takmer všetky rakovinové bunky sú pokryté proteínom nazývaným CD47, ktorý dokáže hrať signál „nejedz ma“. na makrofágy.
Weissman and colleagues later developed an antibody called Hu5F9-G4 that blocks the CD47 protein and encourages macrophages to engulf cancer cells. Rituximab is an antibody that has been shown to amplify the positive ” eat me ” signal. The combination of rituximab and Hu5F-G4 has previously been shown to be effective against human cancer in animal models, but this is the first published result of clinical trials of the therapy in humans.
Z 22 pacientov zúčastnených na skúške malo 11 pacientov signifikantne zníženú klinickú rakovinu a 8 pacientov eliminovalo všetky príznaky rakoviny. Ostatní traja pacienti v klinickom skúšaní nereagovali na liečbu a zomreli v dôsledku progresie ochorenia. Vedci zistili, že účastníci mali iba malé vedľajšie účinky.
Dr. Saul A. Rosenberg , a lymphoma professor , said that such a potential new imunoterapia is very exciting. This is the first time that an antibody that can activate macrophages to fight cancer is used, and it seems to be safe for use in humans.
https://medicalxpress.com/news/2018-10-anti-cd47-cancer-therapy-safe-small.html
